期刊
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
卷 -, 期 -, 页码 256-263出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/asheducation-2018.1.256
关键词
-
资金
- National Cancer Institute [K23 CA160345]
- Mayo Clinic Cancer Center/Richard M. Schulze Family Foundation for Awards in Cancer Research
- Fraternal Order of Eagles Cancer Research Fund
- NATIONAL CANCER INSTITUTE [K23CA160345] Funding Source: NIH RePORTER
Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据